jueves, 25 de mayo de 2023

FDA Approves ZYNYZ (retifanlimab-dlwr) for the Treatment of Adult Patients with Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma

label

No hay comentarios:

Publicar un comentario